TY  - JOUR
AU  - Conroy, Jeffrey M
AU  - Pabla, Sarabjot
AU  - Nesline, Mary K
AU  - Glenn, Sean T
AU  - Papanicolau-Sengos, Antonios
AU  - Burgher, Blake
AU  - Andreas, Jonathan
AU  - Giamo, Vincent
AU  - Wang, Yirong
AU  - Lenzo, Felicia L
AU  - Bshara, Wiam
AU  - Khalil, Maya
AU  - Dy, Grace K
AU  - Madden, Katherine G
AU  - Shirai, Keisuke
AU  - Dragnev, Konstantin
AU  - Tafe, Laura J
AU  - Zhu, Jason
AU  - Labriola, Matthew
AU  - Marin, Daniele
AU  - McCall, Shannon J
AU  - Clarke, Jeffrey
AU  - George, Daniel J
AU  - Zhang, Tian
AU  - Zibelman, Matthew
AU  - Ghatalia, Pooja
AU  - Araujo-Fernandez, Isabel
AU  - de la Cruz-Merino, Luis
AU  - Singavi, Arun
AU  - George, Ben
AU  - MacKinnon, Alexander C
AU  - Thompson, Jonathan
AU  - Singh, Rajbir
AU  - Jacob, Robin
AU  - Kasuganti, Deepa
AU  - Shah, Neel
AU  - Day, Roger
AU  - Galluzzi, Lorenzo
AU  - Gardner, Mark
AU  - Morrison, Carl
PY  - 2019
DO  - 10.1186/s40425-018-0489-5
UR  - http://hdl.handle.net/10668/13457
T2  - Journal for immunotherapy of cancer
AB  - PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different...
LA  - en
KW  - Atezolizumab
KW  - Avelumab
KW  - Biomarker
KW  - Durvalumab
KW  - Nivolumab
KW  - PD-L1
KW  - Pembrolizumab
KW  - cancer immunotherapy
KW  - Antineoplastic Agents, Immunological
KW  - B7-H1 Antigen
KW  - Humans
KW  - Immunohistochemistry
KW  - Neoplasms
KW  - RNA, Messenger
KW  - RNA-Seq
TI  - Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
TY  - research article
VL  - 7
ER  -